Leading the early drug discovery research pipeline to discover medicines that improve patients' lives by integrating the prospect of high-value cytoskeletal drug targets with state-of-the-art small molecule drug discovery technologies.

Our mission at Kainomyx is dedicated to aiding the eradication of malaria and other parasitic diseases worldwide by combining the potential of high-value cytoskeleton targets with state-of-the-art small molecule drug discovery technologies. At Kainomyx, we resonate with parity in global health by alleviating health crises that have destroyed developing nations and now threaten the world because of climate change.

Stealth-mode

Lead a biophysics and biochemistry team to help advance novel cardiovascular therapeutics against unique sarcomeric and non-sarcomeric proteins via a precision medicine approach to treat cardiomyopathies and other forms of heart failure that result from contractility defects of the cardiac muscle.

Lead a team of biochemists and biophysicists exploring innovative therapies for the treatment of cardiomyopathies and other forms of heart disease. Transitioned from MyoKardia following its acquisition by Bristol Myers Squibb in November 2020.

Nurtured a strong biochemistry team to develop new cardiovascular therapies against novel sarcomeric proteins. Lead this team to understand the biophysics of the cardiac sarcomere for better screening of small-molecules for unique drug targets.

Built a strong biochemistry team to understand the molecular mechanism of action of different clinical and preclinical molecules in four different cardiovascular programs. In this process helped MyoKardia to take some key go-no-go decisions.

Genetic Diversity and Personalized Medicine – 2019 Extending Life by Controlling Chronic Disease – 2018 The Human Genome and Disease – 2016

Program: Cardiomyopathy and Heart Failure• Project leader in developing assays to understanding how the tunability of the cardiac contractility is affected by the interaction of the myosin enzymatic motor domain with both myosin-binding protein C (MyBPC) and myosin S2 domain in both wild type and cardiomyopathy-causing myosin mutants. • Supervised a project which involved characterization of the enzymatic properties of different cardiomyopathy-causing cardiac myosin mutants in understanding their role in human cardiomyopathies. Performed bulk enzyme kinetic assays and in vitro motility experiments to measure the rates of the various steps of the myosin ATPase cycle. Used single molecule force spectroscopy to characterize the force generated by a single myosin molecule. Finally using loaded in vitro motility showed that the power output of individual myosin molecule is altered because of these mutations. • Directed the efforts of understanding the effects of phosphorylation on the biomechanics of human cardiac myosin. Using force spectroscopy showed that the internal power producing ability of a single myosin head is enhanced upon the phosphorylation of the regulatory light chain associated with it. • Drove a project of understanding the cardiomyopathic causing mutations in the troponin T complex of the regulated thin filament. Used the bacterial expression system to purify the troponin complex proteins. Used steady state fluorescence and stopped-flow kinetic measurements to measure the dynamics of Ca2+ binding and showed that the Ca2+ dissociation kinetics is altered in these mutants.

• Establishing physio-chemical and biophysical assessment of several different monoclonal antibodies, bi-specific antibodies and nano-bodies as lead drug candidates for different immuno-oncological targets. • Leading a research project for development of new high throughput biophysical methodologies as platforms for effective screening of different biologics.